Effectiveness of Istradefylline for Fatigue and Quality of Life in Parkinson’s Disease Patients’ and of Their Caregivers’

Objectives: We evaluated efficacy and safety of istradefylline that is the first selective adenosineA2A receptor antagonist, for the treatment of non-motor symptoms and quality of life (QoL) inParkinson’s disease (PD) patients with and QoL in their caregivers. Methods: This was a multi-sites study of 40 PD patients (female 24, male 16) who fully filled UK PD society brain bank clinicaldiagnostic criteria. They received istradefylline 20 mg/day for 8 weeks. We added istradefyllineon the previous anti-Parkinson’s drugs. Clinical severities were evaluated by Hoehn-Yahr (H-Y)stage, unified PD rating scale (UPDRS), non-motor symptoms in PD (NMSPD), fatigue severity scale(FSS) and Euro QoL. Also, we evaluated their caregiver’s QoL by Euro QoL. Results: The scores ofUPDRS part I improved from 1.3 ± 1.1 to 06 ± 0.9 (P = 0.18), part II improved from 11.9 ± 3.2 to11.0 ± 3.1 (P = 0.17), part III improved from 34.8 ± 7.2 to 32.1 ± 8.3 (P = 0.105). There was no sig-nificant improvement or worsening of the H-Y stages. The scores of NMSPD improved from 49.9 ±11.2 to 43.9 ± 10.6 (P = 0.08). The scores of FSS improved from 62.8 ± 7.1 to 52.3 ± 9.3 (P = 0.049).The total scores of Euro QoL in PD patients improved from 48.8 ± 14.9 to 57.2 ± 13.0 (P = 0.045).The total scores of Euro QoL in patients’ caregivers improved from 54.2 ± 11.0 to 59.8 ± 10.9 (P =0.046). Conclusions: Our data demonstrated that istradefylline was associated with few side ef-fects and was modestly effective for the treatment of non-motor symptoms especially fatigue thatmight improve QoL in PD patients as well as in their caregivers’.